Figure 3
Figure 3. Increased IFN-γ response to stimulation with IL-2, anti-Ly49D, and anti-NKp46 in NKG2D-deficient mice. (A) Percentages of IFN-γ–producing NK cells upon stimulation with IL-2 (1000 U/mL), PMA/ionomycin (upper panel), and IL-18 (5 ng/mL) + IL-12 (125 pg/mL and 250 pg/mL)(lower panel) are shown for 5 to 6 mice/genotype; data are representative of 3 individual experiments. (B) Percentages of IFN-γ–producing NK cells upon stimulation with anti-NK1.1 (25 μg/mL), anti-Ly49D (5 μg/mL), anti-NKp46 (5 μg/mL), and anti-NKG2D (25 μg/mL) antibodies (n = 3-5 mice/genotype). Data are representative of at least 3 independent experiments. (C) Percentages of IFN-γ–producing NK cells among CD27hiCD11blo (“CD27hi”), DP (“CD27+CD11b+”), and CD27loCD11bhi (“CD27lo”) subsets upon anti-Ly49D stimulation (n = 5 mice/genotype). Data are representative of 5 independent experiments.

Increased IFN-γ response to stimulation with IL-2, anti-Ly49D, and anti-NKp46 in NKG2D-deficient mice. (A) Percentages of IFN-γ–producing NK cells upon stimulation with IL-2 (1000 U/mL), PMA/ionomycin (upper panel), and IL-18 (5 ng/mL) + IL-12 (125 pg/mL and 250 pg/mL)(lower panel) are shown for 5 to 6 mice/genotype; data are representative of 3 individual experiments. (B) Percentages of IFN-γ–producing NK cells upon stimulation with anti-NK1.1 (25 μg/mL), anti-Ly49D (5 μg/mL), anti-NKp46 (5 μg/mL), and anti-NKG2D (25 μg/mL) antibodies (n = 3-5 mice/genotype). Data are representative of at least 3 independent experiments. (C) Percentages of IFN-γ–producing NK cells among CD27hiCD11blo (“CD27hi”), DP (“CD27+CD11b+”), and CD27loCD11bhi (“CD27lo”) subsets upon anti-Ly49D stimulation (n = 5 mice/genotype). Data are representative of 5 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal